Statistics about Amyloidosis

Complication statistics for Amyloidosis:

The following are statistics from various sources about the complications of Amyloidosis:

• Less than 15% of patients display the physical characteristics typically associated with amyloidosis i.e. enlargement of tongue, submandibular, swelling, and facial purpura in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Less than 1% of patients with amyloidosis have tongue enlargement in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• In 33-40% of amyloidosis patients, the kidney is affected in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• There is echocardiographic evidence of amyloidosis in about 40% of patients in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• There is congestive heart failure due to amyloidosis in about 20% of patients in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• 1 in 6 amyloid patients have symptomatic liver involvement in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Gastric mucosa biopsies reveal asymptomatic vascular amyloid deposits in 90% of patients with amyloidosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Rectal biopsies reveal asymptomatic vascular amyloid deposits in 80% of patients with amyloidosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• 1% of patients with amyloidosis had symptomatic gastric amylodosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• 6.5% of myeloid patients receiving melphalan eventually develop mylodysplasia in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• more about complications...»

Treatment statistics for Amyloidosis:

The following are statistics from various sources about the treatment of Amyloidosis:

• High-dose dexamethasone had a positive response in less than 15% of amyloid patients with no cardiac involvement in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• 4.6 years was the median survival rate for AL amyloidosis patients who were treated with melphalan and autologous stem-cell transplantation (High-dose Melphalan and Autologous Stem-Cell transplantation in Patients with AL Amyloidosis, Annals of International Medicine, 2004;140:85-93)
• 13% mortality rate for AL amyloidosis patients 100 days after treatment with melphalan and stem-cell transplantation (High-dose Melphalan and Autologous Stem-Cell transplantation in Patients with AL Amyloidosis, Annals of International Medicine, 2004;140:85-93)
• 28% of AL amyloidosis patients showed a response to treatment with oral melphalan and prednisone in the US (Blood first Edition Paper, 2003;DOI 10.1182)
• 30% of AL amyloidosis patients who showed a response to treatment with oral melphalan and prednisone took a year to respond in the US (Blood first Edition Paper, 2003;DOI 10.1182)
• more about treatments...»

Prevalence and incidence statistics for Amyloidosis:

See also prevalence and incidence page for Amyloidosis

Prevalance of Amyloidosis: less than 3,000 people in the US (Mayo Clinic)

Prevalance Rate: approx 1 in 90,666 or 0.00% or 3,000 people in USA [about data]

Prevelance statistics about Amyloidosis:

The following statistics relate to the prevalence of Amyloidosis:

• 60 to 65% of cases of amyloidosis occurs in men in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Only 1% of amyloidosis patients are under 40 in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• more about prevalence...»

Incidence statistics about Amyloidosis:

The following statistics relate to the incidence of Amyloidosis:

• 1,200 to 3,200 new cases each year for AL Amyloidosis in the US (Amyloidosis Support Network)
• more about incidence...»

Amyloidosis Prevalence: Book Excerpts

• Causes and incidence - Amyloidosis

Death statistics for Amyloidosis:

The following are statistics from various sources about deaths and Amyloidosis:

• 35% of deaths from secondary AA amyloidosis is due to end-stage renal failure resulting from untreated secondary AA amyloidosis n the US (Amyloidosis Support Network)
• more about deaths...»

Survival rate statistics for Amyloidosis:

The following are statistics from various sources about the survival rate for Amyloidosis:

• 1 year is the median survival rate for patients who have a liver biopsy to treat amyloidosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Symptomatic congestive heart failure has a median survival of 4 to 6 months in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• 8 months is the median survival for amyloidosis patients from the onset of myelodysplasia in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Amyloid patients with cardiac involvement who undergo heart transplant have a 100% 1 year survival rate in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• Amyloid patients with cardiac involvement who undergo heart transplant have a 83.3% 2 year survival rate in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
• The five year survival rate for secondary AA Amyloidosis is about 50% in the US (Amloidosis Support Network)
• The 1 year survival rate for patients with primary systemic amyloidosis who undergo peripheral blood stem cell transplantation is 89% (Blood. 2004;103:3960-3963, The American Society of Hematology)
• The 1 year survival rate for patients with primary systemic amyloidosis who don’t undergo peripheral blood stem cell transplantation is 55% (Blood. 2004;103:3960-3963, The American Society of Hematology)
• The 2 year survival rate for patients with primary systemic amyloidosis who undergo peripheral blood stem cell transplantation is 71% (Blood. 2004;103:3960-3963, The American Society of Hematology)
• The 2 year survival rate for patients with primary systemic amyloidosis who don’t undergo peripheral blood stem cell transplantation is 71% (Blood. 2004;103:3960-3963, The American Society of Hematology)
• The 4 year survival rate for patients with primary systemic amyloidosis who undergo peripheral blood stem cell transplantation is 81% ((Blood. 2004;103:3960-3963, The American Society of Hematology)
• The 4 year survival rate for patients with primary systemic amyloidosis who don’t undergo peripheral blood stem cell transplantation is 41% (Blood. 2004;103:3960-3963, The American Society of Hematology)
• The median survival rate for AL amyloidosis is 12-18 months in the US (The Mayo Clinic)
• 51% is the 1 year survival rate for patients with AL Amyloidosis (Long-Term Survival in 30 Patients With Primary Amyloidosis, The American Society of Hematology, 1999)
• 16% is the 5 year survival rate for patients with AL Amyloidosis (Long-Term Survival in 30 Patients With Primary Amyloidosis, The American Society of Hematology, 1999)
• 4.7% is the 10 year survival rate for patients with AL Amyloidosis (Long-Term Survival in 30 Patients With Primary Amyloidosis, The American Society of Hematology, 1999)
• 100% of AL amyloidosis patients who survived more than 10 years had received alkylating-agent therapy (Long-Term Survival in 30 Patients With Primary Amyloidosis, The American Society of Hematology, 1999)
• more about deaths...»

Society statistics for Amyloidosis

Hospitalization statistics for Amyloidosis:

The following are statistics from various sources about hospitalizations and Amyloidosis:

• 0.008% (995) of hospital consultant episodes were for amyloidosis in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 86% of hospital consultant episodes for amyloidosis required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 57% of hospital consultant episodes for amyloidosis were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 43% of hospital consultant episodes for amyloidosis were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 23% of hospital consultant episodes for amyloidosis required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 9.4 days was the mean length of stay in hospitals for amyloidosis in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 3 days was the median length of stay in hospitals for amyloidosis in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 60 was the mean age of patients hospitalised for amyloidosis in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 43% of hospital consultant episodes for amyloidosis occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 11% of hospital consultant episodes for amyloidosis occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 43% of hospital consultant episodes for amyloidosis were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.007% (3,849) of hospital bed days were for amyloidosis in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)

About statistics:

This page presents a variety of statistics about Amyloidosis. The term 'prevalence' of Amyloidosis usually refers to the estimated population of people who are managing Amyloidosis at any given time. The term 'incidence' of Amyloidosis refers to the annual diagnosis rate, or the number of new cases of Amyloidosis diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

 » Next page: Statistics by Country for Amyloidosis

Rate This Website

What do you think about the features of this website? Take our user survey and have your say:

Website User Survey

Medical Tools & Articles:

Next articles:

• Statistics by Country for Amyloidosis
• Hospital Statistics for Amyloidosis
• Articles about Amyloidosis
• Glossary for Amyloidosis
• Clinical Trials for Amyloidosis

Tools & Services:

• Bookmark this page
• Take a survey relating to Amyloidosis
• Symptom Search
• Symptom Checker
• Medical Dictionary
• Give your feedback

Medical Articles:

• Disease & Treatments Search
• Misdiagnosis Center
• Full list of interesting articles

Forums & Message Boards

• Ask or answer a question at the Boards:
• I cannot get a diagnosis. Please help.
• Tell us your medical story.
• Share your misdiagnosis story.
• What is the best treatment for my condition?
• See all the Boards.

Enter your search terms Submit search form
Search The Web Search wrongdiagnosis.com

Common Health Mistakes

Symptom
Checker

Search Specialists by State and City